MARKET

PCVX

PCVX

Vaxcyte, Inc.
NASDAQ
44.50
-0.09
-0.20%
After Hours: 44.50 0 0.00% 17:56 12/12 EST
OPEN
44.80
PREV CLOSE
44.59
HIGH
44.93
LOW
43.52
VOLUME
1.72M
TURNOVER
--
52 WEEK HIGH
94.60
52 WEEK LOW
27.66
MARKET CAP
5.83B
P/E (TTM)
-9.1978
1D
5D
1M
3M
1Y
5Y
1D
Promising Potential of Vaxcyte’s VAX-31 Vaccine Drives Buy Rating
TipRanks · 4d ago
Vaxcyte (PCVX): Reassessing Valuation After OPUS Phase 3 Trial Start for Next-Generation Pneumococcal Vaccine
Simply Wall St · 5d ago
Vaxcyte (PCVX) Gets a Buy from Guggenheim
TipRanks · 5d ago
Vaxcyte’s Strategic Phase 3 Trial Initiation and Its Market Implications
TipRanks · 6d ago
Vaxcyte Announces First Participants Dosed In OPUS Phase 3 Pivotal, Noninferiority Trial Evaluating VAX-31 For Prevention Of Invasive Pneumococcal Disease And Pneumonia In Adults
Benzinga · 6d ago
Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31
TipRanks · 6d ago
Vaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Adults
Reuters · 6d ago
VAXCYTE DOSES FIRST PARTICIPANTS IN THE OPUS PHASE 3, NONINFERIORITY TRIAL EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN ADULTS
Reuters · 6d ago
More
About PCVX
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.

Webull offers Vaxcyte Inc stock information, including NASDAQ: PCVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCVX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCVX stock methods without spending real money on the virtual paper trading platform.